Skip to main
ZYXI
ZYXI logo

Zynex Inc (ZYXI) Stock Forecast & Price Target

Zynex Inc (ZYXI) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Zynex Inc has demonstrated strong financial performance, evidenced by a 16% year-over-year growth in orders for fiscal year 2024, which reflects a robust demand for its electrotherapy and pain management devices. The company aims to enhance revenue generation by increasing sales per representative to $1 million, positioning itself for future growth. Additionally, Zynex's commitment to reducing reliance on opioids through advanced, non-opioid therapies, along with substantial cost reductions projected to save approximately $35 million annually, underscores its potential for improved profitability and market influence.

Bears say

Zynex Inc. has demonstrated a concerning financial outlook, highlighted by a projected 37% year-over-year decline in Q1 sales, anticipated to reach "at least $30 million." The company reported a Q4 revenue of $46 million, which represents a 3% decline compared to the previous year and fell short of internal projections. Additionally, Zynex is facing significant challenges, including potential regulatory hurdles and increased competition in the pain management sector, leading to a reevaluation of future sales expectations, now estimated to drop by 28% to $140 million in 2025.

Zynex Inc (ZYXI) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zynex Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zynex Inc (ZYXI) Forecast

Analysts have given Zynex Inc (ZYXI) a Buy based on their latest research and market trends.

According to 6 analysts, Zynex Inc (ZYXI) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zynex Inc (ZYXI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.